UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas

UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
Recruiting
18 years - 64 years
All
Phase 1
5 participants needed
1 Location

Brief description of study

Non-Hodgkin lymphoma  is a potentially curable condition with standard cancer treatment drugs (chemotherapy) and steroids. Standard lymphoma treatment includes chemotherapy, or cancer-fighting drugs, called etoposide, vincristine, cyclophosphamide, prednisone and doxorubicin (called EPOCH).
 



Detailed description of study

The main purpose of this study is to test the safety of an oral drug, ibrutinib, added to the standard lymphoma treatment.
 We will also study whether ibrutinib has a helpful effect against HIV and other viruses in our bodies that can cause lymphoma.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Non-Hodgkin lymphoma,Diffuse Large B-cell Lymphoma,HIV+,
  • Age: 18 years - 64 years
  • Gender: All

  1. Participants must have documented CD20 positive or negative diffuse large B-cell lymphoma (DLBCL).
  2. Stage II-IV disease.
  3. Documentation of HIV diagnosis.
  4.  Be 18–64 yrs of age.

Updated on 04 Aug 2024. Study ID: 828995

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center